“They must prove now not only that their science works, but also convince a price sensitive health care system to adopt it.”

“Start-up companies are focused on advancing their research,” said Opus Biotech cofounder Dan Eramian, “but unless they can compellingly articulate the value of their unique stories to investors early on, they risk leaving their technology in the lab.”

Eramian and cofounder Charles Craig have a combined four decades experience in public relations, investor relations, government affairs and reputation building.

“Start-up companies live in a highly competitive environment,” said Craig. “They must prove now not only that their science works, but also convince a price sensitive health care system to adopt it.”

Eramian served as the first vice president of communications for the Biotechnology Industry Organization (BIO) during the industry’s transformation from fascinating science to global health care innovator. He has managed challenging communications and investor relations at public and private biotech companies and served on their management boards. Eramian was also chief spokesman for two national federal agencies, the Department of Justice and the Small Business Administration.

Craig has been on the front lines of the biotech revolution as president of Georgia Bio and as a writer, editor and communicator for the Biotechnology Industry Organization (BIO), BioWorld Today and annual Ernst & Young Global Biotechnology Report. During his 30-year career, he also worked as a writer and editor for mainstream newspapers, magazines, and television news.

For more information on Opus Biotech Communications visit www.opusbiotech.com and contact Dan Eramian at 425-306-8716 or danieleramian@comcast.net; and Charles Craig at 404-245-0591 or charles.s.craig@gmail.com.